Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Ubivac announced it raised $80,000 in an initial filing
PRIVATEAug 27, 2026•about 3 hours ago
Amount Raised
$80,000
Round Type
Pre-Seed
PortlandBiotechnologyHealthcare
Company Information
Company
UbiVac
Location
18183 S.W. BOONES FERRY ROAD
Portland, Oregon, United States
About
UbiVac has unique and disruptive immune educating and activating vaccine technology. UbiVac’s lead agent, DPV-001, contains the newly discovered non-mutated shared cancer neoantigens and more than 300 antigens for the majority of patients with adenocarcinoma or squamous cell cancers. Due to its unique platform vaccine technology, novel targets are being discovered that might be used for ADC, CAR-T/NK, and TCR gene therapy. UbiVac postulates that by applying machine learning, artificial intelligence, and generative adversarial networks to the analysis of the extensive monitoring data from these ongoing first-in-human trials, new insights will allow future trials to tailor treatment regimens and further improve outcomes of patients with cancer.
Don't miss UbiVac's next move
Get an email the moment UbiVac raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
Suggested for you
1 contact
Verified contacts3 people are listed at UbiVac. We don't have their email yet.
PortlandBiotechnologyHealthcare